SCHEMBL12102401

SCHEMBL12102401

NC(=O)CCCC(C(=O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 2/20 0.54
ALOX15 P16050 1/20 0.54
BLM P54132 1/20 0.54
KMT2A Q03164 1/20 0.54
ENPEP Q07075 3/20 0.41
FOLH1 Q04609 3/20 0.39
GSR P00390 2/20 0.39
CYP1A2 P05177 2/20 0.39
GRM8 O00222 1/20 0.39
GRM6 O15303 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIK1 P39086 1/20 0.39
GRM5 P41594 1/20 0.39
GRIA1 P42261 1/20 0.39
GRIA2 P42262 1/20 0.39
GRIA3 P42263 1/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31612214 0.90 PMP22 (0.50) PMP22ALOX15BLMKMT2AENPEP
SCHEMBL2797202 0.80 LMNA (0.56) PMP22BLMKMT2AENPEPFOLH1
SCHEMBL3739405 0.79 KMT2A (0.77) PMP22ALOX15BLMKMT2AGSR
SCHEMBL12102395 0.79 KMT2A (0.39) PMP22ALOX15BLMKMT2AENPEP
SCHEMBL5328651 0.79 KMT2A (0.77) PMP22ALOX15BLMKMT2AGSR
SCHEMBL14437177 0.79 KMT2A (0.77) PMP22ALOX15BLMKMT2AGSR
SCHEMBL9308206 0.78 ENPEP (0.43) BLMENPEPFOLH1GSRTET2
SCHEMBL12851496 0.78 GSR (0.43) ENPEPGSRMAPTRNPEP
SCHEMBL27611006 0.77 RNPEP (0.61) PMP22ALOX15BLMKMT2AENPEP
SCHEMBL27537439 0.76 KMT2A (0.58) PMP22ALOX15BLMKMT2AENPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
US-20110269706-A1 Hydroxamic Acid Derivatives NORTHLAKE BIOSCIENCES LLC (US) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269706-A1 Hydroxamic Acid Derivatives CD74, HLA-DRB1, HDAC5 PMP22 3189/4885ALOX15 412/4885BLM 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.